Life sciences partner Katherine Wang (Shanghai) was quoted in a Pink Sheet article on Mar. 14 that discusses the impact of a new proposal by China’s State Council to reduce the number of state agencies overseeing drug regulation.
The plan would merge the nation’s top drug regulator, China FDA, into a new combined body called the National Regulatory and Management Commission, and create a medical reimbursement agency to oversee China’s health insurance policy-making, in a move designed to strengthen regulatory oversight.
Ms. Wang explains that the proposal is potentially a separation of pre-market and post-market functions into two agencies. The impact to the China drug industry could be different standards in enforcing the regulations.
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.